Wuxi AppTec Corporate Ventures has participated in a round that will support development of NuProbe's molecular blood test.
US-based medical diagnostics technology developer NuProbe has received $11m in a series A round featuring WuXi AppTec Corporate Ventures, healthcare group WuXi AppTec’s corporate venturing unit.
Sequoia Capital China, an affiliate firm of venture capital firm Sequoia Capital, co-led the round with hedge fund manager Serica Partners.
NuProbe has developed a molecular blood test that helps medical researchers promptly detect rare genetic variants that could be indicative of diseases such as cancer. The test works by identifying malignant instances of…
